Clinical Trials

The NSCC's Radiation Oncology research team consists of internationally recognised Oncologists, Medical Physicists, Radiation Therapists, and Radiologists, supported by experienced research staff. The team also collaborates with studies developed elsewhere, by other Australian and international experts, to contribute further to knowledge advancement.

Patients who are having radiation therapy at Royal North Shore Hospital might be eligible to participate in one or more clinical trials being conducted here at NSCC. Your Radiation Oncologist will speak with you about the treatment outcomes that are important to you and whether any of the clinical trials being conducted here in Radiation Oncology might suit your interests.

Radiation Therapist treating a patient with prostate cancer on the KIM gating trial 

We are currently recruiting to clinical trials in the following treatment areas. For more information on any of the trials listed, please speak with your Radiation Oncologist.




The AGOG Epidemiology Study aims to determine which genetic and environmental

factors affect the diagnosis and response to treatment of brain glioma.

AGOG trial: AGOG website




This study is for women receiving post−mastectomy or post−lumpectomy radiotherapy who are oestrogen receptor and/or progesterone receptor positive. It was designed to determine the best timing of the commencement of the anti-oestrogen medication Anastrozole: before radiotherapy or after radiotherapy.

STARS trial: TROG  

STARS trial: trials registry

STARS trial: study details 




This is a research study using a new technology which adjusts the radiotherapy beam to account for the movement of lung tumours as the patient breathes. "SABR" stands for Stereotactic Ablative Body Radiotherapy (also known as SBRT) and is therefore a study specifically for Lung SABR. It uses Calypso® beacons for tumour motion tracking during the treatment.

LIGHT SABR trial: study details




This study is for lung cancer patients who will be receiving a course of standard Radiotherapy (ie. not SABR). The aim of Radiotherapy is to deliver the radiation as precisely as possible to the lesion and to spare nearby organs such as the healthy lung, heart and liver. However, breathing can cause organ motion during treatment. If we can help the patient to monitor and regulate their breathing using an audio-visual guidance device, we may be able to more accurately target the radiation beam to the cancer.

AVIATOR trial: trials registry


CT Ventilation

This is a research study for lung radiotherapy which will investigate if it is possible to obtain information about lung function (working lung areas vs. non-working lung areas) from a type of computed tomography scan (CT scan) known as a four dimensional computed tomography scan (4D-CT scan). It is hoped that this lung function information can be incorporated into the planning of radiotherapy treatment for lung cancer patients, in order to reduce treating the areas of the lungs that are doing the most work. The information may also minimise potential damage to the lungs and radiotherapy treatment side-effects.

CT Ventilation trial: trials registry



Cross PET

This is a research study in oesophageal cancer patients undergoing chemoradiotherapy followed by surgery, and is investigating the accuracy of a PET (Positron Emission Tomography) scan in predicting response to chemoradiation.

Cross PET trial: trials registry



KIM Gating

This pilot study will assess the improved accuracy of a new tumour targeting technology available on standard radiotherapy treatment devices, called Kilovoltage Intrafraction Monitoring (KIM). KIM allows monitoring of the tumour position during delivery of radiotherapy and has the ability to stop and adapt if the tumour moves.

We are the only site in the world offering this new technology. This study is important because it potentially provides highly accurate targeting to standard radiotherapy treatment devices and will be highly transferable to other Institutions.

KIM Gating trial: study details



The primary aim of this study is to assess the side-effects of Stereotactic Body Radiation Therapy (SBRT) boost at three increasing dose levels given before administration of standard fractionation external beam radiotherapy in patients being treated for prostate adenocarcinoma.

Booster trial: study details



The primary aim of this study is to compare the safety and effectiveness of giving fewer radiotherapy treatments for prostate cancer at a higher dose per treatment. This clinical trial was developed at Miami University and we are the only site in Australia where this study is available.

HEAT trial: study details 



This study compares the effectiveness of standard androgen deprivation therapy and radiation therapy combined either with enzalutamide or with currently available anti-androgen drugs. The main aim of the study is to see which of these combinations of treatment is better for improving the survival of men with prostate cancer who have not had their prostate removed, and who are at a higher than normal risk of their cancer coming back. This is the first study evaluating the potential benefit of enzalutamide in this patient group.

The study is being conducted in Australia, New Zealand, Ireland and the USA.


ENZARAD trial: trials registry

ENZARAD trial: study details



This study aims to asses the optimal timing of radiotherapy in post prostatectomy patients with high risk features: straight after radical prostatectomy or only when, after surgery, there is a rising PSA indicating active cancer.





This is a research study looking at Magnetic Resonance Imaging (MRI) and Positron Emission Tomography/Computer Tomography (PET/CT) imaging to predict how rectal cancers may respond to chemotherapy combined with radiation therapy.

PRISM trial: study details